These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1658 related articles for article (PubMed ID: 27910859)

  • 41. Functionalized biomimetic nanoparticles combining programmed death-1/programmed death-ligand 1 blockade with photothermal ablation for enhanced colorectal cancer immunotherapy.
    Xiao Y; Zhu T; Zeng Q; Tan Q; Jiang G; Huang X
    Acta Biomater; 2023 Feb; 157():451-466. PubMed ID: 36442821
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Human Pancreatic Carcinoma-Associated Fibroblasts Promote Expression of Co-inhibitory Markers on CD4
    Gorchs L; Fernández Moro C; Bankhead P; Kern KP; Sadeak I; Meng Q; Rangelova E; Kaipe H
    Front Immunol; 2019; 10():847. PubMed ID: 31068935
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Targeting the immune microenvironment for ovarian cancer therapy.
    Blanc-Durand F; Clemence Wei Xian L; Tan DSP
    Front Immunol; 2023; 14():1328651. PubMed ID: 38164130
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical Significance of Tumor-Infiltrating T Cells and Programed Death Ligand-1 in Patients with Pancreatic Cancer.
    Yoshida S; Ito Z; Suka M; Bito T; Kan S; Akasu T; Saruta M; Okamoto M; Kitamura H; Fujioka S; Misawa T; Akiba T; Yanagisawa H; Sugiyama H; Koido S
    Cancer Invest; 2019; 37(9):463-477. PubMed ID: 31490702
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Co-Stimulatory Bispecific Antibodies Induce Enhanced T Cell Activation and Tumor Cell Killing in Breast Cancer Models.
    Warwas KM; Meyer M; Gonçalves M; Moldenhauer G; Bulbuc N; Knabe S; Luckner-Minden C; Ziegelmeier C; Heussel CP; Zörnig I; Jäger D; Momburg F
    Front Immunol; 2021; 12():719116. PubMed ID: 34484225
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The critical roles of activated stellate cells-mediated paracrine signaling, metabolism and onco-immunology in pancreatic ductal adenocarcinoma.
    Fu Y; Liu S; Zeng S; Shen H
    Mol Cancer; 2018 Feb; 17(1):62. PubMed ID: 29458370
    [TBL] [Abstract][Full Text] [Related]  

  • 47. B7-H5/CD28H is a co-stimulatory pathway and correlates with improved prognosis in pancreatic ductal adenocarcinoma.
    Chen Q; Wang J; Chen W; Zhang Q; Wei T; Zhou Y; Xu X; Bai X; Liang T
    Cancer Sci; 2019 Feb; 110(2):530-539. PubMed ID: 30548441
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Envisioning the immune system to determine its role in pancreatic ductal adenocarcinoma: Culprit or victim?
    Javadrashid D; Baghbanzadeh A; Hemmat N; Hajiasgharzadeh K; Nourbakhsh NS; Lotfi Z; Baradaran B
    Immunol Lett; 2021 Apr; 232():48-59. PubMed ID: 33647329
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers.
    Sweis RF; Galsky MD
    Urol Oncol; 2016 Dec; 34(12):556-565. PubMed ID: 27836246
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immune therapies in pancreatic ductal adenocarcinoma: Where are we now?
    Hilmi M; Bartholin L; Neuzillet C
    World J Gastroenterol; 2018 May; 24(20):2137-2151. PubMed ID: 29853732
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pancreatic ductal adenocarcinoma contains an effector and regulatory immune cell infiltrate that is altered by multimodal neoadjuvant treatment.
    Shibuya KC; Goel VK; Xiong W; Sham JG; Pollack SM; Leahy AM; Whiting SH; Yeh MM; Yee C; Riddell SR; Pillarisetty VG
    PLoS One; 2014; 9(5):e96565. PubMed ID: 24794217
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Therapeutic gene modified cell based cancer vaccines.
    Kozłowska A; Mackiewicz J; Mackiewicz A
    Gene; 2013 Aug; 525(2):200-7. PubMed ID: 23566846
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prevailing over T cell exhaustion: New developments in the immunotherapy of pancreatic cancer.
    Bauer C; Kühnemuth B; Duewell P; Ormanns S; Gress T; Schnurr M
    Cancer Lett; 2016 Oct; 381(1):259-68. PubMed ID: 26968250
    [TBL] [Abstract][Full Text] [Related]  

  • 54. PD-L1 expression in pancreatic ductal adenocarcinoma is a poor prognostic factor in patients with high CD8
    Yamaki S; Yanagimoto H; Tsuta K; Ryota H; Kon M
    Int J Clin Oncol; 2017 Aug; 22(4):726-733. PubMed ID: 28314962
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Perineural Invasion Reprograms the Immune Microenvironment through Cholinergic Signaling in Pancreatic Ductal Adenocarcinoma.
    Yang MW; Tao LY; Jiang YS; Yang JY; Huo YM; Liu DJ; Li J; Fu XL; He R; Lin C; Liu W; Zhang JF; Hua R; Li Q; Jiang SH; Hu LP; Tian GA; Zhang XX; Niu N; Lu P; Shi J; Xiao GG; Wang LW; Xue J; Zhang ZG; Sun YW
    Cancer Res; 2020 May; 80(10):1991-2003. PubMed ID: 32098780
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Activating Immune Recognition in Pancreatic Ductal Adenocarcinoma via Autophagy Inhibition, MEK Blockade, and CD40 Agonism.
    Jiang H; Courau T; Borison J; Ritchie AJ; Mayer AT; Krummel MF; Collisson EA
    Gastroenterology; 2022 Feb; 162(2):590-603.e14. PubMed ID: 34627860
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Overcoming Resistance to Combination Radiation-Immunotherapy: A Focus on Contributing Pathways Within the Tumor Microenvironment.
    Darragh LB; Oweida AJ; Karam SD
    Front Immunol; 2018; 9():3154. PubMed ID: 30766539
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Characterization of tumor-associated T-lymphocyte subsets and immune checkpoint molecules in head and neck squamous cell carcinoma.
    Lechner A; Schlößer H; Rothschild SI; Thelen M; Reuter S; Zentis P; Shimabukuro-Vornhagen A; Theurich S; Wennhold K; Garcia-Marquez M; Tharun L; Quaas A; Schauss A; Isensee J; Hucho T; Huebbers C; von Bergwelt-Baildon M; Beutner D
    Oncotarget; 2017 Jul; 8(27):44418-44433. PubMed ID: 28574843
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Hollow Cu2MoS4 nanoparticles loaded with immune checkpoint inhibitors reshape the tumor microenvironment to enhance immunotherapy for pancreatic cancer.
    Yao Z; Qi C; Zhang F; Yao H; Wang C; Cao X; Zhao C; Wang Z; Qi M; Yao C; Wang X; Xia H
    Acta Biomater; 2024 Jan; 173():365-377. PubMed ID: 37890815
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Tumoral EHF predicts the efficacy of anti-PD1 therapy in pancreatic ductal adenocarcinoma.
    Liu J; Jiang W; Zhao K; Wang H; Zhou T; Bai W; Wang X; Zhao T; Huang C; Gao S; Qin T; Yu W; Yang B; Li X; Fu D; Tan W; Yang S; Ren H; Hao J
    J Exp Med; 2019 Mar; 216(3):656-673. PubMed ID: 30733283
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 83.